News

Net profit of Astrazeneca Pharma India declined 32.06% to Rs 37.93 crore in the quarter ended June 2026 as against Rs 55.83 crore during the previous quarter ended June 2025. Sales rose 29.73% to Rs 682.79 crore in the quarter ended June 2026 as against Rs 526.31 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales682.79526.31 30 OPM %7.1715.41 - PBDT56.2291.63 -39 PBT50.9975.06 -32 NP37.9355.83 -32 Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 10 August 2026.

AstraZeneca Pharma India announced that Bhavana Agrawal, Executive Director and Chief Financial Officer (CFO) has resigned from the position of CFO (Key Managerial Personnel) of the company with effect from the close of business hours on 31 August 2026, pursuant to her appointment to a regional role within the AstraZeneca Group.

Astrazeneca Pharma India announced that the 47th Annual General Meeting(AGM) of the company will be held on 10 August 2026.

AstraZeneca Pharma India has appointed Praveen K Mittal, Director - Corporate Affairs, with effect from 06 July 2026